The global COVID-19 pandemic has led to new challenges for the life-sciences industry and accelerated changes which were predicted to take place over years, rather than months.
Our team of strategic consultants have spent the last few months collaborating with our medical and commercial specialists to investigate the impact of the virus on the life-sciences industry.
The extensive research included conducting first-hand interviews with clients across the industry, who work across a range of roles and functions at both large pharmaceutical companies and innovative biotechnology organisations.
The results revealed both challenges and opportunities across the entire product life cycle, including:
- The need for innovation in the way clinical trials are designed to ensure products can continue to be developed in the new normal
- The optimization of product launches and go-to-market models for a post-pandemic-world
- A shift in the way customers expect to interact with life-sciences companies, including new requirements for customer engagement
- Novel services to better facilitate the doctor-patient relationship.
It is clear the pandemic will have lasting implications for the way life-sciences companies operate internally and externally. To see a snapshot of our findings, download the infographic below.
For a deeper analysis of the COVID-19 landscape and the implications for your organization, contact firstname.lastname@example.org